Mixed-model repeated-measures analyses showed significant ( P < @ ) and/or clinically meaningful improvements ( small to moderate ) from baseline in favor of trametinib for global health ; physical , role , and social functioning ; fatigue ; pain ; insomnia ; nausea and vomiting ; constipation ; dyspnea ; and appetite at weeks @ and/or @ .